Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Arcellx, Inc.

Get SEC filing alerts via email and in your feed for Arcellx, Inc.

ACLX

Arcellx, Inc.

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies using its proprietary D-Domain platform to create safer, more effective, and broadly accessible CAR-T treatments. Its core products include ddCARs—single infusion CAR-T therapies—and ARC-SparX, a controllable universal CAR-T system. Targeting hematologic cancers, solid tumors, and autoimmune diseases, Arcellx leverages engineered synthetic binding domains to improve efficacy, safety, manufacturability, and treatment adaptability.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Arcellx, Inc.

1
1
Arcellx, Inc. Arcellx Reports 2025 Financial Results and Announces Merger Agreement with Gilead

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Arcellx, Inc. Arcellx Reports Q3 2025 Financial Results with Significant Revenue Decline

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Arcellx, Inc. Arcellx Reports Significant Revenue Decline and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Arcellx, Inc. Arcellx Reports 79% Revenue Decline and Increased Operating Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Arcellx, Inc. Arcellx Reports Financial Results for Q3 2024, Net Loss Reduction and Collaboration Revenue Growth

Via official filing (AI summary) | over 1 year ago | 0 comments